Influence of AGTR1 and ABCB1 Gene Polymorphism on the Curative Effect of Irbesartan

Overview

Journal Int J Hypertens

Publisher Wiley

Date 2022 Nov 21

PMID 36404948

Authors

Qiao Wang

Lingsen You

Zeyu Li

Leiyi Zhang

Xueqi Li

Xuesong Yang

Affiliations

Soon will be listed here.

Abstract

The interindividual heterogeneity in response to the antihypertensive effect of irbesartan has received considerable attention because of gene polymorphism. In this study, we investigated the new combinational influences of AGTR1 and ABCB1 gene polymorphism on the therapeutic effect of irbesartan among Chinese hypertensive patients. A total of 353 samples including 168 normal people and 185 hypertensive patients were adopted, and genotypes comprise ABCB1 (CC, CT, and TT) and AGTR1 (AA and AC) in this study. The results of multiple linear regression models showed that no statistically significant differences were observed in blood pressure change following irbesartan administration in each genotype from either ABCB1 (CC, CT, and TT) or AGTR1 (AA and AC). However, spline smoothing analysis demonstrated that the blood pressure therapeutic responses of irbesartan presented a noticeable difference among different ABCB1 genotypes when irbesartan doses reached over 300 ng/mL. Eventually, we assumed that the different drug responses of irbesartan among various AGTR1 genotypes were due to the diversity of the irbesartan-conjugated protein, which is responsible for crossing-coupled intracellular G-protein-coupled receptors (GPCRs).

References

Mohammadabadi M, Bordbar F, Jensen J, Du M, Guo W . Key Genes Regulating Skeletal Muscle Development and Growth in Farm Animals. Animals (Basel). 2021; 11(3). PMC: 7999090. DOI: 10.3390/ani11030835. View

Norouzy A, Nassiry M, Eftekhari Shahrody F, Javadmanesh A, Mohammad Abadi M, Sulimova G . Identification of bovine leucocyte adhesion deficiency (BLAD) carriers in Holstein and Brown Swiss AI bulls in Iran. Genetika. 2006; 41(12):1697-701. View

Jiang S, Hsu Y, Venners S, Zhang Y, Xing H, Wang X . Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. J Hypertens. 2011; 29(5):890-5. DOI: 10.1097/HJH.0b013e32834494f6. View

Nassiry M, Shahroodi F, Mosafer J, Mohammadi A, Manshad E, Ghazanfari S . Analysis and frequency of bovine lymphocyte antigen (BoLA-DRB3) alleles in Iranian Holstein cattle. Genetika. 2005; 41(6):817-22. View

Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C . The value of irbesartan in the management of hypertension. Expert Opin Pharmacother. 2009; 10(11):1817-31. DOI: 10.1517/14656560903103820. View

MohammadabadiM R, Nikbakhti M, Mirzaee H, Shandi M, Saghi D, Romanov M . Genetic variability in three native Iranian chicken populations of the Khorasan province based on microsatellite markers. Genetika. 2010; 46(4):572-6. View

Goodfriend T, Elliott M, Catt K . Angiotensin receptors and their antagonists. N Engl J Med. 1996; 334(25):1649-54. DOI: 10.1056/NEJM199606203342507. View

Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvanen A . The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs..... Am J Hypertens. 2008; 21(7):836-9. DOI: 10.1038/ajh.2008.190. View

Reeves R, Lin C, Kassler-Taub K, Pouleur H . Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998; 31(6):1311-6. DOI: 10.1161/01.hyp.31.6.1311. View

10.

Gillis J, Markham A . Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1998; 54(6):885-902. DOI: 10.2165/00003495-199754060-00007. View

11.

Staessen J, Wang J, Bianchi G, Birkenhager W . Essential hypertension. Lancet. 2003; 361(9369):1629-41. DOI: 10.1016/S0140-6736(03)13302-8. View

12.

Kathawala R, Wang Y, Shukla S, Zhang Y, Alqahtani S, Kaddoumi A . ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chin J Cancer. 2015; 34(3):115-20. PMC: 4593353. DOI: 10.1186/s40880-015-0003-0. View

13.

Hodges L, Markova S, Chinn L, Gow J, Kroetz D, Klein T . Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2010; 21(3):152-61. PMC: 3098758. DOI: 10.1097/FPC.0b013e3283385a1c. View

14.

Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H . Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens. 2004; 17(1):8-13. DOI: 10.1016/j.amjhyper.2003.09.009. View

15.

Schelleman H, Stricker B, de Boer A, Kroon A, Verschuren M, Van Duijn C . Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs. 2004; 64(16):1801-16. DOI: 10.2165/00003495-200464160-00006. View

16.

Mohammadabadi M, Jafari A, Bordbar F . Molecular analysis of CIB4 gene and protein in Kermani sheep. Braz J Med Biol Res. 2017; 50(11):e6177. PMC: 5597282. DOI: 10.1590/1414-431X20176177. View

17.

POOL J, Guthrie R, Littlejohn 3rd T, Raskin P, Shephard A, Weber M . Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998; 11(4 Pt 1):462-70. DOI: 10.1016/s0895-7061(97)00501-3. View

18.

Israili Z, Hernandez-Hernandez R, Valasco M . The future of antihypertensive treatment. Am J Ther. 2007; 14(2):121-34. DOI: 10.1097/01.pap.0000249915.12185.58. View

19.

van den Meiracker A, Admiraal P, Janssen J, Kroodsma J, de Ronde W, Boomsma F . Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995; 25(1):22-9. DOI: 10.1161/01.hyp.25.1.22. View

20.

Forni V, Wuerzner G, Pruijm M, Burnier M . Long-term use and tolerability of irbesartan for control of hypertension. Integr Blood Press Control. 2011; 4:17-26. PMC: 3172075. DOI: 10.2147/IBPC.S12211. View